Diabetic Neuropathy Treatment Market – By Disease Type (Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, Focal Neuropathy), Treatment (Drug Class [Antidepressant], Radiotherapy and Physiotherapy), Distribution Channel, Forecast, 2024 - 2032

Diabetic Neuropathy Treatment Market – By Disease Type (Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, Focal Neuropathy), Treatment (Drug Class [Antidepressant], Radiotherapy and Physiotherapy), Distribution Channel, Forecast, 2024 - 2032

Diabetic Neuropathy Treatment Market Size

Diabetic Neuropathy Treatment Market size was valued at around USD 4.3 billion in 2023 and is estimated to grow at 7.9% CAGR from 2024 to 2032. The increasing prevalence of diabetes is significantly driving the growth of the market.

To get key market trends

  Download Free Sample

As the number of diabetes cases rises, more patients are at risk of developing diabetic neuropathy, a common complication characterized by nerve damage. This surge in diabetic populations necessitates more effective and accessible treatments. For instance, as per the IDF Diabetes Atlas, 537 million adults were living with diabetes - 1 in 10, in 2021. This alarming increase underscores the growing demand for diabetic neuropathy treatments, propelling market expansion and innovation in therapeutic options.

Diabetic neuropathy treatment refers to the medical interventions and strategies aimed at managing and alleviating the symptoms of diabetic neuropathy, a type of nerve damage caused by high blood sugar levels associated with diabetes. The primary goals of treatment include controlling blood glucose levels to prevent further nerve damage, relieving pain and discomfort, and addressing any complications that arise from the condition.
 

What are the growth opportunities in this market?

 Download Free Sample

Diabetic Neuropathy Treatment Market Trends

Recent advancements in the treatment and diagnosis of diabetic neuropathy have significantly contributed to the market growth. These innovations aim to enhance the efficacy of treatments, improve patient outcomes, and provide more precise treatment options and diagnostic tools.

• Gene therapies targeting specific pathways involved in nerve damage are currently in development. These therapies aim to repair or replace defective genes, potentially reversing the damage caused by diabetic neuropathy?.
• Additionally, new classes of drugs, such as sodium-glucose co-transporter-2 (SGLT2) inhibitors, are being investigated for their potential neuroprotective effects. These drugs not only help control blood sugar levels but also may offer benefits in reducing nerve damage.
• Moreover, the development of targeted pain management drugs or therapies, such as monoclonal antibodies against nerve growth factor (NGF), shows promise for providing pain relief specifically for diabetic neuropathy patients.
• As these new therapies become more widely available, they are likely to be adopted into standard practice, further driving market growth.

Diabetic Neuropathy Treatment Market Analysis

Learn more about the key segments shaping this market

 Download Free Sample

Based on disease type, the market is categorized into peripheral neuropathy, autonomic neuropathy, proximal neuropathy, and focal neuropathy. The peripheral neuropathy segment dominated the market, with a revenue share of around 45.4% in 2023.

• Peripheral neuropathy is the most common form of diabetic neuropathy. It affects the legs and feet first, which is a prevalent issue among diabetic patients, making it the largest segment?.
• Additionally, a wide range of therapeutic options are available for managing peripheral neuropathy, including medications like pain management drugs, anticonvulsants, and antidepressants, as well as physical therapy and lifestyle modifications. This availability of numerous approaches attracts the patients and health professionals and contributed to the segmental growth.

Based on treatment, the diabetic neuropathy treatment market is categorized into drug class, radiotherapy and physiotherapy, and other treatments. The drug classes segment dominated the market with USD 2.2 billion in 2023.

• There is a broad range of drug classes available for treating diabetic neuropathy, including anticonvulsants, antidepressants, and pain relievers. This variety allows for personalized treatment plans tailored to individual patient needs.
• Additionally, oral medications are easy to administer and do not require specialized equipment or training, unlike some radiotherapy and physiotherapy treatments. This convenience contributes to their widespread use.

Learn more about the key segments shaping this market

 Download Free Sample

Based on distribution channel, the diabetic neuropathy treatment market is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment dominated the market, with a revenue share of around 44.7% in 2023.

• Hospitals provide essential medical care, from emergency services to specialized treatments. Pharmacies ensure access to prescribed medications, which are often vital for managing health conditions and recovering from illnesses.
• Additionally, the demand for healthcare services is consistently high due to factors like population growth, aging demographics, and the prevalence of chronic diseases. This constant demand contributes to the dominance of hospitals and pharmacies

Looking for region specific data?

 Download Free Sample

North America diabetic neuropathy treatment market accounted for USD 1.9 billion revenue in 2023 and is predicted to witness substantial market growth over the analysis timeline.

• North America has a significant prevalence of diabetes, which is a major risk factor for diabetic neuropathy. As the diabetic population continues to grow, the demand for diabetic neuropathy treatment also increases in the region.
• Additionally, growing awareness among healthcare professionals and patients about the consequences of diabetic neuropathy and the importance of early diagnosis and treatment contributes to market growth in the region.

U.S. diabetic neuropathy treatment market holds a dominant position with the market share of 93.3% in 2023.  

• Ongoing advancements in medical technology lead to the development of innovative treatment options for diabetic neuropathy. This includes new medications, medical devices, and therapeutic approaches that offer improved efficacy and patient outcomes, stimulating market growth.
• Additionally, robust research and development activities in the pharmaceutical and biotechnology sectors drive innovation in diabetic neuropathy treatment. Collaborative efforts between academia, industry, and government organizations lead to the discovery of novel therapeutic targets and the development of promising drug candidates, contributing to market expansion.

Germany diabetic neuropathy treatment market is expected to grow significantly during the forecast period.

• Germany boasts a well-developed healthcare infrastructure with access to advanced diagnostic and treatment services for diabetic neuropathy. Patients have access to a comprehensive network of healthcare providers, specialty clinics, and treatment facilities, driving market demand.
• Additionally, the country has a robust healthcare system with substantial investments in diabetes management and related complications. Increased healthcare spending by the government, insurance companies, and individuals supports the adoption of newer and more expensive treatment options, fueling market growth.

China diabetic neuropathy treatment market is anticipated to witness a high growth rate from 2024-2032, due to several factors.

• The Chinese government has implemented policies to address the growing burden of diabetes and its complications. Initiatives aimed at improving diabetes management, promoting healthy lifestyles, and enhancing access to healthcare services indirectly support market growth by encouraging early intervention and treatment in the country.
• Additionally, China's aging population contributes to the prevalence of diabetes and diabetic neuropathy. As the population ages, there is a larger target market for diabetic neuropathy treatment, driving market growth.

Diabetic Neuropathy Treatment Market Share

The diabetic neuropathy treatment industry is competitive in nature, with various large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel therapeutics with improved efficiency and cost-effectiveness are key market strategies for diabetic neuropathy drugs manufacturers, driving competition and innovation in the industry. This emphasis on innovation aims to address evolving clinical needs and enhance patient outcomes, positioning companies to gain market share and meet the growing demand for novel diabetic neuropathy treatment.

Diabetic Neuropathy Treatment Companies

Some of the eminent market participants operating in the diabetic neuropathy treatment industry include

• Abbott
• Boehringer Ingelheim GmbH
• Eli Lilly and Company
• Glenmark Pharmaceuticals Ltd
• Janssen Pharmaceuticals, Inc
• Lupin Pharmaceuticals
• MEDA Pharma GmBH & Co. KG
• Pfizer Inc.

Diabetic Neuropathy Treatment Industry News

• In May 2024, Eli Lilly and Co's LY-3857210 is under clinical development and currently in Phase II for the treatment of diabetic neuropathic pain. The successful commercialization of this drug will expand Eli Lilly and Co’s product portfolio, offering a new treatment option for diabetic neuropathic pain and further solidifying the company position in the market.
• In January 2023, Abbott announced that the U.S. Food and Drug Administration (FDA) approved its Proclaim XR spinal cord stimulation (SCS) system for the treatment of painful diabetic peripheral neuropathy (DPN). This approval expanded the Abbott neuropathy treatment portfolio and increases its prsence in the  market.

Diabetic neuropathy treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 to 2032 for the following segments

Click here to Buy Section of this Report

Market, By Disease Type

• Peripheral neuropathy
• Autonomic neuropathy
• Proximal neuropathy
• Focal neuropathy

Market, By Treatment

• Drug class
  • Antidepressants
  • Anticonvulsants
  • Non-steroidal anti-inflammatory drugs (NSAIDS)
  • Opioid
  • Other drug classes
• Radiotherapy and physiotherapy
• Other treatments

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa